2022
Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles
Goutman S, Boss J, Iyer G, Habra H, Savelieff M, Karnovsky A, Mukherjee B, Feldman E. Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles. Muscle & Nerve 2022, 67: 208-216. PMID: 36321729, PMCID: PMC9957813, DOI: 10.1002/mus.27744.Peer-Reviewed Original ResearchMeSH KeywordsAmyotrophic Lateral SclerosisBody Mass IndexHumansMetabolomicsPrognosisProspective StudiesConceptsBody mass indexBody mass index trajectoriesMetabolomic profilesAmyotrophic lateral sclerosis survivalAmyotrophic lateral sclerosisAmyotrophic lateral sclerosis participantsMass indexBody mass index lossBody mass index trajectory groupsSelf-reported body heightParticipants lost weightShorter survivalProspective cohortSurvival associationsStudy entryMetabolomic networksGeneralized estimating equationsSymptom onsetBMI trendsWeight lossSurvivalBile acidsBody heightTrajectory groupsPotential mechanisms
2019
Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Mohan D, Lerario A, Else T, Mukherjee B, Almeida M, Vinco M, Rege J, Mariani B, Zerbini M, Mendonca B, Latronico A, Marie S, Rainey W, Giordano T, Fragoso M, Hammer G. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research 2019, 25: 3276-3288. PMID: 30770352, PMCID: PMC7117545, DOI: 10.1158/1078-0432.ccr-18-2693.Peer-Reviewed Original ResearchConceptsUpregulation of cell cycleDNA damage response programsAdrenocortical carcinomaTargeted bisulfite sequencingCancer Genome Atlas projectBisulfite sequencingCpG island hypermethylation phenotypeHypermethylation phenotypeAggressive adrenocortical carcinomasCell cycleMolecular markersBiological processesHypermethylationMolecular diagnosticsShorter disease-freeCancers of patientsBiomarker methylationAtlas projectEfficacious adjuvant therapyLocoregional diseaseOverall survivalAdjuvant therapyAdrenocortical tumorsDismal outcomeSilencing
2018
Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH, Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S, Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee GA, Cotterchio M, Correa M, Curtis KR, Duggan D, Easton DF, English D, Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL, Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM, Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter DJ, Idos GE, Iwasaki M, Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S, Joshi AD, Kolonel LN, Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, LaCroix A, Laurie CA, Lejbkowicz F, Lemire M, Lenz HJ, Levine D, Li CI, Li L, Lieb W, Lin Y, Lindor NM, Liu YR, Loupakis F, Lu Y, Luh F, Ma J, Mancao C, Manion FJ, Markowitz SD, Martin V, Matsuda K, Matsuo K, McDonnell KJ, McNeil CE, Milne R, Molina AJ, Mukherjee B, Murphy N, Newcomb PA, Offit K, Omichessan H, Palli D, Cotoré JPP, Pérez-Mayoral J, Pharoah PD, Potter JD, Qu C, Raskin L, Rennert G, Rennert HS, Riggs BM, Schafmayer C, Schoen RE, Sellers TA, Seminara D, Severi G, Shi W, Shibata D, Shu XO, Siegel EM, Slattery ML, Southey M, Stadler ZK, Stern MC, Stintzing S, Taverna D, Thibodeau SN, Thomas DC, Trichopoulou A, Tsugane S, Ulrich CM, van Duijnhoven FJB, van Guelpan B, Vijai J, Virtamo J, Weinstein SJ, White E, Win AK, Wolk A, Woods M, Wu AH, Wu K, Xiang YB, Yen Y, Zanke BW, Zeng YX, Zhang B, Zubair N, Kweon SS, Figueiredo JC, Zheng W, Le Marchand L, Lindblom A, Moreno V, Peters U, Casey G, Hsu L, Conti DV, Gruber SB. Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal Of The National Cancer Institute 2018, 111: 146-157. PMID: 29917119, PMCID: PMC6555904, DOI: 10.1093/jnci/djy099.Peer-Reviewed Original ResearchTemporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy
2013
Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin L, Fullen D, Giordano T, Thomas D, Frohm M, B. K, Ahn J, Mukherjee B, Johnson T, Gruber S. Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal Of Investigative Dermatology 2013, 133: 2585-2592. PMID: 23633021, PMCID: PMC4267221, DOI: 10.1038/jid.2013.197.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerOverall survivalTissue microarrayPrimary melanomaMelanoma pathogenesisMelanoma progressionAssociated with disease-free survivalAnalysis of tissue microarraysMetastases-free survivalDisease-free survivalHMGA2 overexpressionCox proportional hazards regression modelsLog-rank testPredictors of survivalProportional hazards regression modelsHazards regression modelsBRAF/NRAS mutationsPrimary tumorPrognostic featuresMelanoma metastasesClinicopathological characteristicsReal-time PCRGenetic alterationsAQUA analysisMelanoma development